Exarafenib

Cat. No.: HY-147268

CAS No.: 2639957-39-2

Molecular Formula: $C_{26}H_{34}F_3N_5O_3$

Molecular Weight: 521.58

Target: Raf; p38 MAPK

Pathway: MAPK/ERK Pathway

Storage: 4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (191.73 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	1.9173 mL	9.5863 mL	19.1725 mL
	5 mM	0.3835 mL	1.9173 mL	3.8345 mL
	10 mM	0.1917 mL	0.9586 mL	1.9173 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (4.79 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 2.5 mg/mL (4.79 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

Exarafenib (RAF/KIN_2787) is a potent, orally active pan-RAF inhibitor. Exarafenib has anticancer activity by suppression of downstream MAPK pathway signaling. Exarafenib can be used for cancer research[1][2].

REFERENCES

[1]. Miller N, et, al. Antitumor activity of KIN-2787, a next-generation pan-RAF inhibitor, in combination with MEK inhibition in preclinical models of human NRAS mutant melanoma.2022 Jun 2;40(16): e15099.

[2]. WHO Drug Information. International Nonproprietary Names for Pharmaceutical

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA